

Abstract

In one aspect of the present invention, there is provided a pharmaceutical formulation having a pH of 4.0 to 8.0, comprising (a) an HL161BKN antibody or a fragment thereof, (b) at least one additive selected from mannitol, sorbitol, arginine, histidine, glycine and salts thereof, (c) a buffer system selected from citrate or histidine, and (d) a surfactant. HL161BKN present in the formulation has improved stability and is non-toxic, and thus has a high potential for industrial application.